Morning Read: Valeant still has work to do, Obamacare insurance premiums going up
Also, awkward moments for Blue Shield of California and fresh funding for healthcare mobile apps.
Also, awkward moments for Blue Shield of California and fresh funding for healthcare mobile apps.
Clearly burnt by recent accusations that Valeant Pharmaceuticals is price gouging, its CEO announced that the Canadian company will shift away from M&A activity and focus more on R&D.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also read about the next life science IPO and the Bayer CEO's opinion on American business culture, among other items from the weekend.
Also, a sixth Obamacare co-op had failed, Bristol-Myers Squibb inks a $1.7 billion cancer licensing deal, and learn how Jeb Bush's healthcare reform would impact health IT.
Maybe Martin Shkreli will have a bit of a breather now that Valeant's Michael Pearson is keeping the hot seat warm.
Also news on Cell Therapy, Spark Therapeutics and the quest for an electronic data standard.
Also, MacArthur Awards are in, Medtronic makes its eighth deal of the year, millennials share their opinions on wearables, and does Genentech really have a $5 billion MS drug in the pipeline?
Turing Pharmaceuticals and Martin Shkreli blink (maybe), Anthem-Aetna Capitol Hill testimony begins, and Nestle gets deeper into the medical research.
Valeant Pharmaceuticals is making a $1 billion pitch for Sprout Pharmaceuticals which received FDA approval for a women's libido enhancing drug.
Harvard Business Review’s annual list of the 100 top performing CEOs in the world is out, and four of the top ten are in the healthcare industry. John Martin of Gilead Sciences, David Pyott of Allergan, Lars Rebien Sørensen from Novo Nordisk and J. Michael Pearson, CEO of Valeant Pharmaceuticals all made made it to […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Valeant Pharmaceuticals has bought GlaxoSmithKline's U.S. and Canadian rights to Zovirax, a cold sore treatment. Valeant says that its sales and marketing staff in the United States and Canada can grow the Zovirax brand in North America.
An experimental epilepsy drug co-developed by GlaxoSmithKline has received a recommendation for market approval in Europe. But the drug maker still needs to address Food and Drug Administration concerns before it can get U.S. approval.